Biomedical Engineering Reference
In-Depth Information
with Type 2 diabetes in UK primary care. Diabet. Med. 24(4),
350-358.
18. Bozkaya G, Ozgu E, Karaca B. (2010) The association
between estimated average glucose levels and fasting plasma
glucose levels. Clinics (Sao Paulo) 65(11), 1077-1080.
19. Hamnvik O-PR, McMahon GT. (2009) Balancing risk and
benefit with oral hypoglycemic drugs. Mt. Sinai J. Med. 76(3),
234-243.
20. Adler AI, Shaw EJ, Stokes T, Ruiz F. (2009) Newer agents for
blood glucose control in type 2 diabetes: summary of NICE
guidance. BMJ 338, b1668.
21. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E,
Brett JH, et al. (2009) Liraglutide once a day versus exenatide
twice a day for type 2 diabetes: a 26-week randomised,
parallel-group, multinational, open-label
29. Freeman JS. (2011) Optimizing outcomes for GLP-1 agonists.
J. Am. Osteopath. Assoc. 111(2 Suppl. 1), eS15-eS20.
30. Bailey CJ, Kodack M. (2011) Patient adherence to medication
requirements for therapy of type 2 diabetes. Int. J. Clin. Pract.
65(3), 314-322.
31. Pratley RE, Gilbert M. (2008) Targeting incretins in type 2
diabetes: role of GLP-1 receptor agonists and DPP-4 inhibi-
tors. Rev. Diabet. Stud. 5(2), 73-94.
32. Tirrell M. (2010) Regeneron rises as drug matches Roche's in
fewer doses. Bloomberg, 22 November.
33. Grogan K. (2011) Sanofi/Regeneron's aflibercept fails in
NSCLC trial. PharmaTimes, 11 March.
34. Melnikova I. (2005) Wet age-related macular degeneration.
Nat. Rev. Drug Discov. 4(9), 711-712.
35. Brown D. (2005) AMD: underlying causes and treatment:
unraveling angiogenesis. Medscape.
36. Pollack A. (2011) Cheaper drug to treat eye disease is effective.
New York Times, 28 April.
37. Baghdadi R. (2007) The Lucentis/Avastin investigation: the
story is far from over. In Vivo, 13 December.
38. Johnson D, Hollands H, Hollands S, Sharma S. (2010)
Incidence and characteristics of acute intraocular inflamma-
tion after intravitreal injection of bevacizumab: a
retrospective cohort study. Can. J. Ophthalmol. 45(3),
239-242.
39. Dennis M. (2010) Studies: Bayer, Regeneron's VEGF Trap-
Eye matches Lucentis in patients with wet AMD. FirstWord,
22 November.
40. McCallister E.
trial
(LEAD-6).
Lancet 374(9683), 39-47.
22. Chua S, Chan S. (2011) Medication adherence and achieve-
ment of glycaemic targets in ambulatory type 2 diabetic
patients. J. Appl. Pharm. Sci. 1(4), 55-59.
23. Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR.
(2010) Glucagon-like peptide analogues for type 2 diabetes
mellitus: systematic review and meta-analysis. BMC Endocr.
Disord. 10, 20.
24. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. (2009)
Potential of albiglutide, a long-acting GLP-1 receptor agonist,
in type 2 diabetes: a randomized controlled trial exploring
weekly, biweekly, and monthly dosing. Diabetes Care 32(10),
1880-1886.
25. Jimenez-Solem E, Rasmussen MH, Christensen M, Knop
FK. (2010) Dulaglutide, a long-acting GLP-1 analog
fused with an Fc antibody fragment for the potential
treatment of type 2 diabetes. Curr. Opin. Mol. Ther. 12(6),
790-797.
26. Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson
JH, Bastyr EJ III. (2011) The effects of LY2189265, a long-
acting glucagon-like peptide-1 analogue, in a randomized,
placebo-controlled, double-blind study of overweight/obese
patients with type 2 diabetes:
(2010) Wanted: non-inferior pricing,
too.
BioCentury, 6 December.
41. Comfort C. (2010) Genentech/novartis ophthalmics' Lucentis
and Regeneron/Bayer's Aflibercept will become decision
resources' proprietary clinical gold standard for the treatment
of wet age-related macular degeneration in 2013. Decision
Resources, 16 Februray.
42. Pijpers F, Belsey MJ. (2006) Cancer remains the dominant
disease target for biotech through to 2010. J. Commercial
Biotechnol. 12(4), 294-298.
43. Blazynski C, DeGregorio T. (2008) Boom time for biotech?
Informa, 31 December.
44. Cooley T. (2011) New study shows the rate of drug approvals
lower than previously reported. Businesswire, 14 Februray.
45. Levine A. (2009) Licensing and scale economies in the
biotechnology pharmaceutical
the EGO study. Diabetes
Obes. Metab. 13(5), 418-425.
27. Johnson J. (2008) New GLP-1 analogs, mimetics in the pipe-
line for type 2 diabetes. Endocrine Today, December.
28. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD,
Fineman MS, et al. (2005) Effects of exenatide (exendin-4) on
glycemic control over 30 weeks in patients with type 2 diabetes
treated with metformin and a sulfonylurea. Diabetes Care
28(5), 1083-1091.
industry. RWJ Sch. Health
Policy Res. April.
Search WWH ::
Custom Search